RxDataLab Research

Our research ranges from quick analyses of market movements and companies to comprehensive deep dives on therapeutic areas and companies. All pieces are grounded in data and designed to cut through industry noise.

Eikon Therapeutics fundraising activity based on form D filings with the SEC.

Jun 22, 2025 • Nicholas George

Eikon Therapeutics Talks Platforms but Bets Big on Acquired Oncology Assets

Eikon Therapeutics has raised over $1B and claims to have a revolutionary drug discovery platform, but its clinical pipeline remains dominated by acquired oncology assets. This report analyzes Eikon’s funding, trials, and patent strategy to assess whether its platform is delivering.

Newsletter Brief Report

Plot of the number of rare epilepsy interventional studies started per year from 2018 through June 2025.

Jun 10, 2025 • rxdatalab team

Bright Minds's Spike Wasn't Random- It was Serotonin

After Lundbeck’s $2B acquisition of Longboard, investors scrambled for serotonin analogs. Here’s why Bright Minds was the target and what it says about the future of rare epilepsy drug development.

Newsletter Brief Report